GlobeNewsWire
20 Jul 2026, 21:33 UTC · 10h ago
IMMX INVESTOR ALERT: Holzer & Holzer, LLC Announces Investigation of Immix Biopharma, Inc.
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
20 Jul 2026, 21:33 UTC · 10h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
Immix Biopharma terminated its Chief Medical Officer after reports emerged that the individual used a false identity and was a captured fugitive. — Severe failure in corporate governance and executive vetting creates massive credibility risks and potential operational instability.
-0.90Holzer & Holzer, LLC has launched an investigation into whether Immix Biopharma complied with federal securities laws. — The prospect of securities litigation and potential regulatory penalties increases financial risk and investor uncertainty.
-0.60Which stocks this story touches
The company is under investigation for securities law compliance following the termination of its CMO who was allegedly a fugitive using a false identity.
Continue reading
6 related stories
Search tags
Mentioned as a subject of a class action lawsuit deadline reminder.
Mentioned as a subject of a class action lawsuit deadline reminder.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
